← Back to patent-cliff list
CAS 41353-91-7
4-azaspiro[bicyclo[2.2.2]octane-2,2'-oxirane]
Codes: CEVI-002
Application context (from source-drug indications)
Sjögren's syndromeCevimeline Hydrochloride Hydrate口腔干燥Cevimeline Hydrochloride HydrateRadiation injuryCevimeline Hydrochloride Hydrate口腔疾病Cevimeline Hydrochloride HydrateHead and neck cancerCevimeline Hydrochloride Hydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Cevimeline Hydrochloride Hydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-azaspiro[bicyclo[2.2.2]octane-2,2'-oxirane]→quinuclidin-3-one hydrochloride→S-((3-hydroxyquinuclidin-3-yl)methyl) ethanethioate ethanethioate→1,1-diethoxyethane
4-azaspiro[bicyclo[2.2.2]octane-2,2'-oxirane]→quinuclidin-3-one hydrochloride→1,1-diethoxyethane→3-(bromomethyl)quinuclidin-3-ol hydrobromide
4-azaspiro[bicyclo[2.2.2]octane-2,2'-oxirane]→quinuclidin-3-one hydrochloride→S-(1-ethoxyethyl) ethanethioate→3-(((1-ethoxyethyl)thio)methyl)quinuclidin-3-ol→3-(((1-ethoxyethyl)thio)methyl)quinuclidin-3-ol benzoate→ethanethioic S-acid→ethoxyethene
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.